AbbVie price target raised to $220 from $218 at Raymond James

Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $220 from $218 and keeps an Outperform rating on the shares. AbbVie had solid top- and bottom-line beats in Q4, setting the stage as an improving growth story with better-than-expected 2025 guidance and Skyrizi and Rinvoq long-term guidance, the analyst tells investors in a research note. The firm believes the pipeline is largely upside and could help drive multiple expansion down the road.